Limits...
Cytokeratin19-2g2, a novel fragment of cytokeratin19 in serum, indicating a more invasive behavior and worse prognosis in breast cancer patients.

Kong Y, Wang J, Liu W, Chen Q, Yang J, Wei W, Wu M, Yang L, Xie X, Lv N, Guo J, Li L, Gao J, Xie X, Dai S - PLoS ONE (2013)

Bottom Line: However, so far, few markers have been proved clinically useful except CA153.The sensitivities of CK19-2G2 for breast carcinoma are as high as CEA and CA153, and up to 71% in MBC patients.Serum CK19-2G2 levels (≥2 mU/mL) were associated with pathological stages, tumor size (≥2 cm), lymph node involvement, and HER2 status.

View Article: PubMed Central - PubMed

Affiliation: Department of Breast Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, PR China.

ABSTRACT

Background: Various studies have been searching for new tumor biomarkers for breast cancer for years. However, so far, few markers have been proved clinically useful except CA153. Based on knowledge that most adenocarcinomas including breast carcinoma expressed Cytokeratin19, the authors studied CK19-2G2,a novel fragment of cytokeratin19 shedding into serum in breast cancer patients.

Patients and methods: The serum samples of four hundred and seventeen patients including three hundred and three (fifty-four DCIS and two hundred and forty-nine stage I-III) PBC patients and one hundred and fourteen MBC patients, eighty-one healthy controls and twenty-one breast benign disease patients were provided for measurement of CK19-2G2, CEA and CA153.The correlation between clinicopathological characters, prognosis and CK19-2G2 levels was further studied.

Results: The serum CK19-2G2 levels in breast cancer patients were significantly higher than that in healthy and benign controls. For breast cancer patients, CK19-2G2 levels in MBC were significantly higher than that in PBC patients. The sensitivities of CK19-2G2 for breast carcinoma are as high as CEA and CA153, and up to 71% in MBC patients. Serum CK19-2G2 levels (≥2 mU/mL) were associated with pathological stages, tumor size (≥2 cm), lymph node involvement, and HER2 status. Multivariate analysis revealed that high serum CK19-2G2 level was an independent factor for relapse (P = 0.029) and death (P = 0.040) in breast cancer patients.

Conclusion: Serum CK19-2G2 may be an independent indicator for prognosis and a candidate marker for monitoring metastasis in breast cancer.

Show MeSH

Related in: MedlinePlus

Serum CK19-2G2 levels in breast cancer patients.(A) The Mean of serum CK19-2G2 levels in healthy, benign, BC group. Serum CK19-2G2 levels in breast cancer patients are higher than those in the healthy and benign controls respectively.(BC vs Benign, P<0.001; BC vs Normal, P<0.001) (Mann-Whitney U test).Error bars are referring to SE(Standard Error). (B) The Mean of serum CK19-2G2 levels in breast cancer patients with LuminalA/B, HER2-enriched and Triple negative type. There was no difference among the three groups.Error bars are referring to SE(Standard Error).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3585311&req=5

pone-0057092-g001: Serum CK19-2G2 levels in breast cancer patients.(A) The Mean of serum CK19-2G2 levels in healthy, benign, BC group. Serum CK19-2G2 levels in breast cancer patients are higher than those in the healthy and benign controls respectively.(BC vs Benign, P<0.001; BC vs Normal, P<0.001) (Mann-Whitney U test).Error bars are referring to SE(Standard Error). (B) The Mean of serum CK19-2G2 levels in breast cancer patients with LuminalA/B, HER2-enriched and Triple negative type. There was no difference among the three groups.Error bars are referring to SE(Standard Error).

Mentions: There was a difference in the distribution of serum CK19-2G2 levels among breast cancer patients, Benign and Healthy controls.(Figure1A). Serum CK19-2G2 levels in breast cancer patients (Mean = 3.66 mU/ml, SE = 0.61 mU/ml) were significantly higher than those of the healthy group (Mean = 0.58 mU/ml, SE = 0.07 mU/ml) and the benign group (Mean = 1.01 mU/ml, SE = 0.17 mU/ml). No increased serum CK19-2G2 levels were observed in both healthy (Range 0–1.96 mU/ml) and benign groups (Range 0–1.98 mU/ml) and there was no difference between the healthy and benign group(P = 0.21). Therefore, the specificity of serum CK19-2G2 for breast carcinoma was 100% (specificity: samples without breast carcinoma with negative tests/all samples without breast carcinoma tested).


Cytokeratin19-2g2, a novel fragment of cytokeratin19 in serum, indicating a more invasive behavior and worse prognosis in breast cancer patients.

Kong Y, Wang J, Liu W, Chen Q, Yang J, Wei W, Wu M, Yang L, Xie X, Lv N, Guo J, Li L, Gao J, Xie X, Dai S - PLoS ONE (2013)

Serum CK19-2G2 levels in breast cancer patients.(A) The Mean of serum CK19-2G2 levels in healthy, benign, BC group. Serum CK19-2G2 levels in breast cancer patients are higher than those in the healthy and benign controls respectively.(BC vs Benign, P<0.001; BC vs Normal, P<0.001) (Mann-Whitney U test).Error bars are referring to SE(Standard Error). (B) The Mean of serum CK19-2G2 levels in breast cancer patients with LuminalA/B, HER2-enriched and Triple negative type. There was no difference among the three groups.Error bars are referring to SE(Standard Error).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3585311&req=5

pone-0057092-g001: Serum CK19-2G2 levels in breast cancer patients.(A) The Mean of serum CK19-2G2 levels in healthy, benign, BC group. Serum CK19-2G2 levels in breast cancer patients are higher than those in the healthy and benign controls respectively.(BC vs Benign, P<0.001; BC vs Normal, P<0.001) (Mann-Whitney U test).Error bars are referring to SE(Standard Error). (B) The Mean of serum CK19-2G2 levels in breast cancer patients with LuminalA/B, HER2-enriched and Triple negative type. There was no difference among the three groups.Error bars are referring to SE(Standard Error).
Mentions: There was a difference in the distribution of serum CK19-2G2 levels among breast cancer patients, Benign and Healthy controls.(Figure1A). Serum CK19-2G2 levels in breast cancer patients (Mean = 3.66 mU/ml, SE = 0.61 mU/ml) were significantly higher than those of the healthy group (Mean = 0.58 mU/ml, SE = 0.07 mU/ml) and the benign group (Mean = 1.01 mU/ml, SE = 0.17 mU/ml). No increased serum CK19-2G2 levels were observed in both healthy (Range 0–1.96 mU/ml) and benign groups (Range 0–1.98 mU/ml) and there was no difference between the healthy and benign group(P = 0.21). Therefore, the specificity of serum CK19-2G2 for breast carcinoma was 100% (specificity: samples without breast carcinoma with negative tests/all samples without breast carcinoma tested).

Bottom Line: However, so far, few markers have been proved clinically useful except CA153.The sensitivities of CK19-2G2 for breast carcinoma are as high as CEA and CA153, and up to 71% in MBC patients.Serum CK19-2G2 levels (≥2 mU/mL) were associated with pathological stages, tumor size (≥2 cm), lymph node involvement, and HER2 status.

View Article: PubMed Central - PubMed

Affiliation: Department of Breast Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, PR China.

ABSTRACT

Background: Various studies have been searching for new tumor biomarkers for breast cancer for years. However, so far, few markers have been proved clinically useful except CA153. Based on knowledge that most adenocarcinomas including breast carcinoma expressed Cytokeratin19, the authors studied CK19-2G2,a novel fragment of cytokeratin19 shedding into serum in breast cancer patients.

Patients and methods: The serum samples of four hundred and seventeen patients including three hundred and three (fifty-four DCIS and two hundred and forty-nine stage I-III) PBC patients and one hundred and fourteen MBC patients, eighty-one healthy controls and twenty-one breast benign disease patients were provided for measurement of CK19-2G2, CEA and CA153.The correlation between clinicopathological characters, prognosis and CK19-2G2 levels was further studied.

Results: The serum CK19-2G2 levels in breast cancer patients were significantly higher than that in healthy and benign controls. For breast cancer patients, CK19-2G2 levels in MBC were significantly higher than that in PBC patients. The sensitivities of CK19-2G2 for breast carcinoma are as high as CEA and CA153, and up to 71% in MBC patients. Serum CK19-2G2 levels (≥2 mU/mL) were associated with pathological stages, tumor size (≥2 cm), lymph node involvement, and HER2 status. Multivariate analysis revealed that high serum CK19-2G2 level was an independent factor for relapse (P = 0.029) and death (P = 0.040) in breast cancer patients.

Conclusion: Serum CK19-2G2 may be an independent indicator for prognosis and a candidate marker for monitoring metastasis in breast cancer.

Show MeSH
Related in: MedlinePlus